What is HC Wainwright's Estimate for CervoMed Q3 Earnings?

Key Points

• HC Wainwright estimates that CervoMed will report a Q3 2025 earnings per share of ($0.66) and maintains a "Neutral" rating with a price target of $11.00.
• The consensus estimate for CervoMed's full-year earnings is projected at ($1.88) per share, with sequential estimates indicating continued losses into subsequent quarters.
• CervoMed stock currently has an average rating of "Moderate Buy" across analysts, with a consensus price target of $19.29.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for CervoMed in a report released on Monday, September 8th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.66) per share for the quarter. HC Wainwright currently has a "Neutral" rating and a $11.00 target price on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed's Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.60) EPS, Q1 2026 earnings at ($0.73) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.53) EPS.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.13). CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.45 million.

Other analysts have also issued research reports about the company. D. Boral Capital upped their target price on CervoMed from $15.00 to $31.00 and gave the stock a "buy" rating in a report on Monday, August 18th. Chardan Capital restated a "buy" rating and issued a $15.00 price objective on shares of CervoMed in a research note on Monday, August 11th. Canaccord Genuity Group upped their price objective on CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Finally, Roth Capital restated a "buy" rating and issued a $16.00 price objective (down previously from $20.00) on shares of CervoMed in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CervoMed has a consensus rating of "Moderate Buy" and an average price target of $19.29.

CervoMed Stock Performance

CRVO traded down $0.40 on Thursday, hitting $8.15. 53,043 shares of the company were exchanged, compared to its average volume of 1,847,516. CervoMed has a 12 month low of $1.80 and a 12 month high of $19.50. The company has a market cap of $75.34 million, a PE ratio of -3.13 and a beta of -0.72. The stock's fifty day moving average is $8.94 and its 200-day moving average is $8.31.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in CervoMed during the 4th quarter worth $32,000. Rhumbline Advisers raised its position in CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after purchasing an additional 1,526 shares during the last quarter. Marshall Wace LLP bought a new position in shares of CervoMed in the 2nd quarter worth about $76,000. Thompson Davis & CO. Inc. bought a new position in shares of CervoMed in the 2nd quarter worth about $88,000. Finally, Nuveen Asset Management LLC raised its position in shares of CervoMed by 113.6% in the 4th quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock worth $97,000 after acquiring an additional 22,104 shares in the last quarter. 25.15% of the stock is currently owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.